Literature DB >> 22480740

Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.

Francesco Viola1, Giulio Barteselli, Laura Dell'arti, Diego Vezzola, Edoardo Villani, Chiara Mapelli, Laura Zanaboni, Maria D Cappellini, Roberto Ratiglia.   

Abstract

PURPOSE: To describe and classify patterns of abnormal fundus autofluorescence (FAF) of patients with β-thalassemia receiving long-term treatment with deferoxamine (DFO).
DESIGN: Prospective, cross-sectional, case-control study. PARTICIPANTS: A total of 197 consecutive patients with β-thalassemia major or intermedia with at least 10 years of treatment with DFO were recruited in a tertiary referral center in Milan, Italy, and were investigated. Seventy-nine thalassemic patients without a history of chelation therapy were included as a control group.
METHODS: All of the patients were investigated using best-corrected visual acuity (BCVA), fundus photography, and FAF imaging by confocal scanning laser ophthalmoscopy (cSLO) and were compared with the control group. MAIN OUTCOME MEASURES: Identification of abnormal FAF patterns in thalassemic patients treated with long-term DFO and their progression and relationship with visual function.
RESULTS: Abnormal FAF not related to other diseases was observed in 18 of the 197 patients (9%) and was classified into 4 phenotypic patterns: minimal change, focal, patchy, and speckled. The abnormal increased or decreased FAF was bilateral in all the cases, and only in some cases did it correspond to funduscopically visible alterations. There were no FAF abnormalities in the control group. During the follow-up, progressive FAF changes related to retinal pigment epithelium (RPE) damage occurred in the patchy pattern, associated with decreasing BCVA. Patients with speckled and focal patterns showed limited or no changes in FAF during the follow-up. No changes in FAF were found in patients with a minimal change pattern. No treated patient with a normal baseline examination demonstrated FAF changes. Patients with patterns other than the minimal change showed significant BCVA deterioration (P<0.001).
CONCLUSIONS: Various phenotypic patterns of abnormal FAF can be identified with cSLO imaging. Fundus autofluorescence is a helpful, fast, and noninvasive tool for monitoring the status of the macula in patients at risk of DFO toxicity. It may be useful in the decision to discontinue or switch the therapy in cases of particular high risk for disease progression. The progressive alteration of the RPE suggests an important role of pathologic RPE changes in the evolution of visual loss during long-term treatment with DFO.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22480740     DOI: 10.1016/j.ophtha.2012.01.039

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  Diabetic retinal pigment epitheliopathy: fundus autofluorescence and spectral-domain optical coherence tomography findings.

Authors:  Eui Chun Kang; Yuri Seo; Suk Ho Byeon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-06       Impact factor: 3.117

2.  Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.

Authors:  Maria Dettoraki; Antonis Kattamis; Ioannis Ladas; Konstantinos Maragkos; Chryssanthi Koutsandrea; Klio Chatzistefanou; Konstantinos Laios; Dimitrios Brouzas; Marilita M Moschos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-30       Impact factor: 3.117

Review 3.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

Review 4.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048

5.  Deferoxamine-induced electronegative ERG responses.

Authors:  Ruben Jauregui; Karen Sophia Park; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang
Journal:  Doc Ophthalmol       Date:  2018-05-16       Impact factor: 2.379

Review 6.  Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.

Authors:  Maura Di Nicola; Giulio Barteselli; Laura Dell'Arti; Roberto Ratiglia; Francesco Viola
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

7.  Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.

Authors:  Cheng-Hsiu Wu; Chao-Ping Yang; Chi-Chun Lai; Wei-Chi Wu; Yi-Hsing Chen
Journal:  BMC Ophthalmol       Date:  2014-07-02       Impact factor: 2.209

Review 8.  β-Thalassemia and ocular implications: a systematic review.

Authors:  Aliki Liaska; Petros Petrou; Constantinos D Georgakopoulos; Ramza Diamanti; Dimitris Papaconstantinou; Menelaos G Kanakis; Ilias Georgalas
Journal:  BMC Ophthalmol       Date:  2016-07-08       Impact factor: 2.209

Review 9.  Clinical applications of fundus autofluorescence in retinal disease.

Authors:  Madeline Yung; Michael A Klufas; David Sarraf
Journal:  Int J Retina Vitreous       Date:  2016-04-08

10.  Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.

Authors:  Constantine D Georgakopoulos; Foteini Tsapardoni; Elli V Kostopoulou; Olga E Makri
Journal:  BMC Ophthalmol       Date:  2018-09-12       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.